NASDAQ$NVCT
Nuvectis Pharma Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported fiscal year 2023 financial results and provided a business update.
Nuvectis Pharma reported its fiscal year 2023 financial results, highlighting progress with its clinical-stage drug candidates NXP800 and NXP900, including the initiation of clinical trials and presentation of preclinical data. The company's cash and cash equivalents were $19.1 million as of December 31, 2023, and the net loss for the year was $22.3 million.
- Initiated Phase 1b clinical trial for NXP800 in platinum-resistant ARID1a-mutated ovarian carcinoma.
- Started investigator-sponsored clinical trial for NXP800 in cholangiocarcinoma in collaboration with the Mayo Clinic.
- Began Phase 1a dose escalation clinical trial for NXP900.
- Expects several catalysts in 2024 for NXP800 and NXP900, including preliminary clinical data updates.
Headline financials
Revenue & EPS history
Nuvectis Pharma · Revenue · Quarterly
$0
Forward guidance
Nuvectis Pharma anticipates several catalysts in 2024 for both NXP800 and NXP900, with updates expected from all clinical trials throughout the year.
Tailwinds
- Preliminary clinical data update expected later this month from the NXP800 Phase 1b study in platinum resistant ARID1a-mutated ovarian cancer.
- Updates expected from all clinical trials throughout the year.
- Focus on developing precision medicines for oncology.
- Cash efficient operations.
- Highly focused on mission.
Headwinds
- Uncertainties regarding the outcomes of clinical trials.
- Risks associated with drug development.
- Dependence on successful clinical trial results and regulatory approvals.
- Potential for delays in clinical trial timelines.
- Competition in the biopharmaceutical industry.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+2.4%
Avg return
Earnings day
+7.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
65%
13 / 20 earnings
Positive
+29.2%
Q3 2024
Best reaction
-14.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.4% | +31.6% | +8.8% | |
| Q4 2026 | +0.5% | +0.2% | +3.3% | |
| Q3 2025 | -7.9% | -3.5% | +6.1% | |
| Q2 2025 | -5.4% | -17.7% | -10.6% | |
| Q1 2025 | +6.4% | +8.3% | -9.4% | |
| Q4 2024 | -5.8% | -9.1% | +31.1% | |
| Q3 2024 | +29.2% | +71.3% | -24.6% | |
| Q1 2024 | -14.9% | -15.3% | -13.6% | |
| Q4 2023 | -4.5% | -0.4% | -25.1% | |
| Q3 2023 | -7.9% | -6.6% | -8.4% | |
| Q2 2023 | +1.4% | +1.1% | -7.0% | |
| Q1 2023 | +5.8% | +6.3% | +14.0% | |
| Q4 2022 | -7.1% | -9.5% | +9.2% | |
| Q3 2021 | +0.9% | -3.5% | +7.7% | |
| Q3 2022 | +0.9% | -3.5% | +7.7% | |
| Q2 2021 | +1.1% | +10.1% | -0.6% | |
| Q2 2022 | +2.6% | -3.0% | -3.7% | |
| Q1 2021 | +18.8% | +28.8% | -24.4% | |
| Q4 2021 | +18.8% | +33.6% | -15.6% | |
| Q1 2022 | +5.4% | +25.2% | -19.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro